Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05998395 · ClinicalTrials.gov registry record · Phase 1
JAK/STAT Inhibition in CNS Kohlmeier-Degos Disease
A Phase 1 study of Kohlmeier-Degos Disease and Kohlmeier Degos Disease With Neurologic Involvement, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
- 1
- Study location
NCT05998395 is a Phase 1 study of Kohlmeier-Degos Disease and Kohlmeier Degos Disease With Neurologic Involvement that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 1 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05998395, a Phase 1 study of Kohlmeier-Degos Disease and Kohlmeier Degos Disease With Neurologic Involvement, has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
- 1
- Study location
Study Summary
Background: Kohlmeier-Degos (K-D) is a rare disease that leads to the inflammation and/or blockage of small blood vessels in many organs; these can include the skin, eyes (rare), small bowels, lungs, heart, and the brain and spinal cord (central nervous system, or CNS). There are no known effective treatments for K-D that affects the CNS. Objective: To test a drug (ruxolitinib) in a person with K-D affecting the CNS. Eligibility: This study is designed to treat 1 adult participant with K-D affecting the CNS. Design: The participant will be screened: They will have a physical exam and blood tests. They will have skin biopsies: Small samples of skin will be removed. They will have a lumbar puncture: A needle will be inserted in his back to draw fluid from the space around the spinal cord. They will have a magnetic resonance imaging (MRI) scan: they will lie on a table that slides into a tube to take pictures of their brain and spinal cord. They will see a doctor who specializes in nerves. Ruxolitinib is a tablet taken by mouth. The participant will take the drug twice a day for up to 26 weeks. The dosage may change over time. The participant will have up to 7 clinic visits in 28 weeks. Each visit will be 1 to 3 days. MRI scans, biopsies, lumbar punctures, and other blood tests will be repeated on different visits. The participant may receive follow-up phone calls between visits. The participant will report any adverse effects. Unscheduled visits may be needed if new symptoms develop. The last follow-up will be 4 weeks after the last dose of the study drug.
Conditions Studied
Interventions
- DRUG Ruxolitinib
Study Locations (1)
Maryland
- National Institutes of Health Clinical Center - Bethesda
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2023-09-28 |
| Est. Completion | 2025-02-28 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05998395
The ClinicalTrials.gov registry entry for NCT05998395 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Heart, Lung, and Blood Institute (NHLBI), which has 501 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Kohlmeier-Degos Disease appearing as the primary indexed condition, and to 1 intervention - of which Ruxolitinib is the first listed.
NCT05998395 reports 1 study location spanning 1 distinct geographic area - top geographies include Maryland.
Frequently Asked Questions
What is clinical trial NCT05998395 about?
NCT05998395 is a clinical study titled "JAK/STAT Inhibition in CNS Kohlmeier-Degos Disease". Background: Kohlmeier-Degos (K-D) is a rare disease that leads to the inflammation and/or blockage of small blood vessels in many organs; these can include the skin, eyes (rare), small bowels, lungs, heart, and the brain and spinal cord (central nervous system, or CNS). There are no known effective...
What is the current status of trial NCT05998395?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2023-09-28. Estimated completion is 2025-02-28.
What conditions does trial NCT05998395 study?
This clinical trial studies the following conditions: Kohlmeier-Degos Disease, Kohlmeier Degos Disease With Neurologic Involvement.
What interventions are being tested in trial NCT05998395?
The interventions under investigation include: Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT05998395?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05998395 being conducted?
This trial has 1 study location across Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kohlmeier-Degos Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Explore more on PlainTrial
Kohlmeier-Degos Disease
All registered trials for this condition
Kohlmeier Degos Disease With Neurologic Involvement
All registered trials for this condition
Maryland
All trials with a study site in Maryland
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.